PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas

• DOI: 10.1158/1078-0432.ccr-06-0292
• Publication Date: 2006-06-15T20:09:26Z
• Authors: Frank Schönleben; Wanglong Qiu; Nancy T. Ciau; Daniel J. Ho; Xiaojun Li; John D. Allendorf; Helen E. Remotti; Gloria H. Su
• Keywords: Adult; Aged, 80 and over; Male; Class I Phosphatidylinositol 3-Kinases; Exons; Middle Aged; Carcinoma, Papillary; 3. Good health; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; 03 medical and health sciences; 0302 clinical medicine; Mutation; Humans; Female; Aged; Carcinoma, Pancreatic Ductal

Abstract Purpose: Recent studies have reported high frequencies of somatic mutations in the phosphoinositide-3-kinase catalytic-α (PIK3CA) gene various human solid tumors. More than 75% those are clustered helical (exon 9) and kinase domains 20). The three hot-spot mutations, E542K, E545K, H1047R, been proven to elevate lipid activity PIK3CA activate Akt signaling pathway. mutational status intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) has not evaluated previously. Experimental Design: To evaluate a possible role for tumorigenesis IPMN IPMC, exons 1, 4, 5, 6, 7, 9, 12, 18, 20 were analyzed 36 IPMN/IPMC two cystadenoma specimens by direct genomic DNA sequencing. Results: We identified four missense nine screened from (11%). One previously as mutation. remaining T324I, W551G, S1015F, novel somatic. Conclusion: This is first report mutation pancreatic cancer. Our data provide evidence that oncogenic properties contribute IPMN/IPMC.